UPDATE 1-BridgeBio Pharma's heart disease drug meets main goal in late-stage study https://ift.tt/wkdF3V5

The company said no safety concerns were identified in patients, adding that it intends to submit marketing applications to the US Food and Drug Administration before the end of 2023, with regulatory filings in additional markets to follow in 2024.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/jqD2mze
Share:

No comments:

Post a Comment

Search This Blog

Powered by Blogger.

Labels

Labels

Blog Archive

Recent Posts

Unordered List

  • Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
  • Aliquam tincidunt mauris eu risus.
  • Vestibulum auctor dapibus neque.

Pages

Theme Support

Need our help to upload or customize this blogger template? Contact me with details about the theme customization you need.